Artiva Axes 94% of Workforce, Weighs Strategic Alternatives After Two Patients in Phase IIa Trial Die

T2Covered by 1 source · first reported by Fierce Biotech / Fierce Healthcare / MedCity / GEN at 27 Oct, 19:30 UTC

In announcing the layoffs and strategic alternatives review, Artiva disclosed that two patients in the trial who underwent the study treatment died in Grade 5 safety events. One patient succumbed to leukoencephalopathy while the second experienced sudden death. The post Artiva Axes 94% of…

businessscience

Sources

• T2Artiva Axes 94% of Workforce, Weighs Strategic Alternatives After Two Patients in Phase IIa Trial DieFierce Biotech / Fierce Healthcare / MedCity / GEN27 Oct, 19:30